Texas Capital Bank Wealth Management Services Inc Invests $48,000 in Aileron Therapeutics, Inc. (NASDAQ:ALRN)

Texas Capital Bank Wealth Management Services Inc acquired a new position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,773 shares of the company’s stock, valued at approximately $48,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.32% of Aileron Therapeutics at the end of the most recent reporting period.

Separately, Sigma Planning Corp purchased a new stake in Aileron Therapeutics in the 4th quarter worth $51,000. Institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Trading Down 2.1 %

ALRN stock traded down $0.08 during trading on Friday, reaching $3.77. The company’s stock had a trading volume of 19,489 shares, compared to its average volume of 124,433. Aileron Therapeutics, Inc. has a 1 year low of $1.01 and a 1 year high of $7.42. The company’s fifty day moving average is $5.11 and its 200-day moving average is $4.04.

Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings data on Monday, April 15th. The company reported ($1.54) EPS for the quarter. On average, analysts predict that Aileron Therapeutics, Inc. will post -0.62 EPS for the current fiscal year.

Insider Buying and Selling at Aileron Therapeutics

In other Aileron Therapeutics news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $4.21, for a total transaction of $85,526.15. Following the completion of the transaction, the insider now owns 1,779,306 shares of the company’s stock, valued at approximately $7,490,878.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $4.21, for a total value of $85,526.15. Following the completion of the transaction, the insider now owns 1,779,306 shares of the company’s stock, valued at approximately $7,490,878.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $4.95, for a total transaction of $53,192.70. Following the completion of the transaction, the insider now directly owns 1,799,711 shares of the company’s stock, valued at approximately $8,908,569.45. The disclosure for this sale can be found here. Insiders own 5.57% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH increased their price target on Aileron Therapeutics from $9.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.